Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.
about
Microglia Ontology and SignalingB Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsRegression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosisInefficient clearance of myelin debris by microglia impairs remyelinating processesComparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequityThe role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Contribution of genome-wide association studies to scientific research: a pragmatic approach to evaluate their impact.Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosisReduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis.Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple SclerosisGene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis.Beta-interferon exposure and onset of secondary progressive multiple sclerosis.Multiple Sclerosis International Federation: stimulating international cooperation in researchMHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies.Remyelinating strategies in multiple sclerosis.Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression.Progressive MS: from pathophysiology to drug discovery.The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.Adjustment modes in the trajectory of progressive multiple sclerosis: a qualitative study and conceptual model.Nogo-A Antibodies for Progressive Multiple Sclerosis.Sudan black: a fast, easy and non-toxic method to assess myelin repair in demyelinating diseases.Bibliometric profile of the global scientific research on multiple sclerosis (2003-2012).An adaptive clinical trials procedure for a sensitive subgroup examined in the multiple sclerosis context.Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial.Endurance training is feasible in severely disabled patients with progressive multiple sclerosis.Access to and Use of Clinical Services and Disease-Modifying Therapies by People with Progressive Multiple Sclerosis in the United Kingdom.The benefits of exercise in progressive MS: some cautious optimism.Advancing trial design in progressive multiple sclerosis.Imag(in)ing multiple sclerosis: Time to take better pictures.White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis.'Progressive MS - macro views': The need for novel clinical trial paradigms to enable drug development for progressive MS.Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring.The Arm Function in Multiple Sclerosis Questionnaire (AMSQ): development and validation of a new tool using IRT methods
P2860
Q26742077-FA5B8D36-DE63-4338-98AE-580861F9AB9BQ26770664-36C6F964-C216-4CE3-ACEC-29A7BABDBA0FQ26998513-2B078CA9-94C7-4BD3-8ECA-B5212B05B2DEQ30276131-805B4440-542C-4788-8E78-69742B32B85CQ30636334-987AF595-A9A6-46A0-882B-8D3DF2101CA7Q33848186-2CB1A1D5-FA13-4468-B94E-EDF4A250F06BQ34170954-51FE69E2-EAD5-4D13-9D19-A73D6CB1636EQ34468304-A3AE9D30-17D1-4B09-9D5F-5D7D530A68D0Q34963504-9AC02348-FB3E-44B4-AC95-33DCBD6E5C84Q35126308-7870FF37-3B19-4B84-8746-C008F6339FA6Q36186773-3323DD7D-E252-46D3-8BF3-14DBFEAC48BBQ36276516-4F3E11F8-3495-4981-B963-856F20AFC359Q36353053-A6DA0828-6F70-43EA-A613-3C65B16801AEQ36484443-DCCB6003-3DE7-4FA6-B9F9-02CF4590A7FFQ37184238-71EC8997-B030-44F6-8576-9E38C17BAD53Q37225075-44A29CB7-9BA9-4EB5-B8E3-582B0DE00005Q37291581-DD86BE06-2534-46F9-BD8B-0FBBD86C03AEQ37397820-1B528229-5337-4F64-8FE6-B56868E927BDQ38261543-B856BC55-8885-45D1-9A64-3CABC5654509Q38407791-5BE9BA64-5152-446B-B105-7BB436ED8BB0Q38585418-EA2FD27D-0C11-4575-955F-2A248F597099Q38629185-9AE96CEC-1350-4D58-AEAD-CADD375C16DCQ38777488-69F9C044-E178-4599-9016-D96C6890CF57Q39010894-E84B53E2-27D4-4DF3-B2AA-C43EEF455709Q41599503-B1F7906D-17C8-4AE7-853E-FAC62978C2E4Q43762789-4AB76ED3-3C41-420C-843A-DD5E3D9EC982Q43763237-E1D97CAE-9981-4885-8C80-ABB74C77BD74Q43987083-2FD43463-173A-4051-9B32-33B165E71FDDQ44475746-CD8CD760-4483-48FC-82F9-A7467F8EA2BEQ47155370-7F8F9287-33C1-4EA5-9BEA-9F2EF4E60157Q47909419-579A80D3-A6FA-488C-B2A3-AA9439F71E02Q48014541-F8C95B97-721E-4FF5-BC85-1B4648965CCAQ48478781-8E087B3A-7DF9-4076-AC9D-4F706E4DEB1FQ49047027-782829FB-E9E5-4D1A-B178-170D5FD00CC0Q50084570-26F8D28C-5784-4A52-A209-3EA97BE26E41Q54963540-854D3375-D04A-4E76-819D-526962DB96C2Q55423399-B3707C8C-798B-498A-891F-F5A3D18325EDQ59149655-3EB896C4-C105-4346-8246-AFBB8D9EFC9E
P2860
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Setting a research agenda for ...... llaborative on Progressive MS.
@ast
Setting a research agenda for ...... llaborative on Progressive MS.
@en
type
label
Setting a research agenda for ...... llaborative on Progressive MS.
@ast
Setting a research agenda for ...... llaborative on Progressive MS.
@en
prefLabel
Setting a research agenda for ...... llaborative on Progressive MS.
@ast
Setting a research agenda for ...... llaborative on Progressive MS.
@en
P2093
P2860
P921
P356
P1476
Setting a research agenda for ...... llaborative on Progressive MS.
@en
P2093
Ahmed Toosy
Anthony Feinstein
David Baker
Dhia Chandraratna
Doug Brown
Kersten Sharrock
Kim Zuidwijk
Marco Salvetti
Olga Ciccarelli
P2860
P304
P356
10.1177/1352458512458169
P5008
P577
2012-08-23T00:00:00Z
2012-11-01T00:00:00Z